STAMFORD, Conn., Feb. 01 11, 2022 (GLOBE NEWSWIRE) — Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced plans to strengthen its market access team to increase market access for the company’s platform. Key team initiatives include improving commercial and reimbursement capabilities, developing new partnerships and strengthening existing relationships with payers and clinicians, and expanding patient access.
Jerry Conway has been appointed Senior Vice President of Market Access to lead these initiatives and accelerate other market access initiatives already underway at Sema4. He will report to Isaac Ro, Chief Financial Officer. Mr. Conway has industry-leading experience working effectively with payers to achieve broad coverage across a variety of industry models, including value-based payment from Medicare, employers, and commercial payers. He brings more than 30 years of Fortune 500 and start-up experience, including Foundation Medicine, Genzyme Genetics and, most recently, Scipher Medicine, where he served as Senior Vice President of Access to market and business development.
Under Mr. Conway’s leadership, Sema4 plans to expand its market access team and payor-specific programs to improve coverage and value-based payment of the market-leading genomics solutions portfolio of the company, Centrellis®optimized insights and data science capabilities. The team will engage with payers to further underscore the value of its offerings, demonstrating how Sema4 can uniquely optimize clinician and patient experience, improve healthcare outcomes and reduce costs.
“Market access is a key strategic area for Sema4,” Mr. Ro said. “Jerry brings a complementary skill set and long track record of success to Sema4, which will help accelerate our business strategy. I am delighted to welcome him to the team and look forward to his future contributions.
“I am excited to join Sema4 as it enables precision medicine solutions that benefit patients, payers and the healthcare system,” said Conway. “I look forward to working with my new colleagues at Sema4 to further expand our platform’s market access and further the company’s mission to transform healthcare through data-driven insights.”
Sema4 is a patient-centric health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 transforms healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and define optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, enables us to generate a more comprehensive understanding of disease and wellness and provide science-based solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners and data should be shared for the benefit of all.
For more information, visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.
Contact with Investor Relations:
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d03e1eea-b490-4629-bad3-a4acadc7d88e